BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

678 related articles for article (PubMed ID: 9876058)

  • 1. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.
    Ferrari S; Mercuri M; Rosito P; Mancini A; Barbieri E; Longhi A; Rimondini S; Cesari M; Ruggieri P; Di Liddo M; Bacci G
    J Chemother; 1998 Dec; 10(6):484-91. PubMed ID: 9876058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase--results of two sequential studies.
    Bacci G; Picci P; Ferrari S; Mercuri M; Brach del Prever A; Rosito P; Barbieri E; Tienghi A; Forni C
    Cancer; 1998 Mar; 82(6):1174-83. PubMed ID: 9506366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
    Grier HE; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Miser JS
    N Engl J Med; 2003 Feb; 348(8):694-701. PubMed ID: 12594313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome.
    Tural D; Molinas Mandel N; Dervisoglu S; Oner Dincbas F; Koca S; Colpan Oksuz D; Kantarci F; Turna H; Selcukbiricik F; Hiz M
    Jpn J Clin Oncol; 2012 May; 42(5):420-6. PubMed ID: 22416252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No advantages in the addition of ifosfamide and VP-16 to the standard four-drug regimen in the maintenance phase of neoadjuvant chemotherapy of Ewing's sarcoma of bone: results of two sequential studies.
    Bacci G; Picci P; Ruggieri P; Ferrari S; Mercuri M; Fabbri N; Rosito P; Barbieri E; Ferraro A; Casadei R
    J Chemother; 1993 Aug; 5(4):247-57. PubMed ID: 8229153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neoadjuvant treatment of Ewing's sarcoma: results obtained in 122 patients treated with a 6-drug chemotherapeutic protocol (vincristine, adriamycin, cyclophosphamide, dactinomycin, ifosfamide and etoposide)].
    Bacci G; Ferrari S; Rosito P; Barbieri E; Mercuri M; Brach del Prever A; Iantorno D; Forni C; Campanacci M
    Minerva Pediatr; 1995 Nov; 47(11):457-69. PubMed ID: 8684341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86.
    Paulussen M; Ahrens S; Dunst J; Winkelmann W; Exner GU; Kotz R; Amann G; Dockhorn-Dworniczak B; Harms D; Müller-Weihrich S; Welte K; Kornhuber B; Janka-Schaub G; Göbel U; Treuner J; Voûte PA; Zoubek A; Gadner H; Jürgens H
    J Clin Oncol; 2001 Mar; 19(6):1818-29. PubMed ID: 11251014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone: recent experience at the istituto rizzoli.
    Bacci G; Ferrari S; Bertoni F; Donati D; Bacchini P; Longhi A; Brach Del Prever A; Forni C; Rimondini S
    J Clin Oncol; 2000 Feb; 18(4):885-92. PubMed ID: 10673532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.
    Miser JS; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Grier HE
    J Clin Oncol; 2004 Jul; 22(14):2873-6. PubMed ID: 15254055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
    Paulussen M; Craft AW; Lewis I; Hackshaw A; Douglas C; Dunst J; Schuck A; Winkelmann W; Köhler G; Poremba C; Zoubek A; Ladenstein R; van den Berg H; Hunold A; Cassoni A; Spooner D; Grimer R; Whelan J; McTiernan A; Jürgens H;
    J Clin Oncol; 2008 Sep; 26(27):4385-93. PubMed ID: 18802150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial.
    Dunst J; Jürgens H; Sauer R; Pape H; Paulussen M; Winkelmann W; Rübe C
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(4):919-30. PubMed ID: 7607966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
    Kushner BH; Meyers PA
    J Clin Oncol; 2001 Feb; 19(3):870-80. PubMed ID: 11157041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors of histological response to primary chemotherapy in Ewing's sarcoma.
    Bacci G; Picci P; Mercuri M; Ferrari S; Longhi A; Cesari M; Rosito P; Mancini AF; Barbieri E; Baldini N
    Acta Oncol; 1998; 37(7-8):671-6. PubMed ID: 10050985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors.
    Wexler LH; DeLaney TF; Tsokos M; Avila N; Steinberg SM; Weaver-McClure L; Jacobson J; Jarosinski P; Hijazi YM; Balis FM; Horowitz ME
    Cancer; 1996 Aug; 78(4):901-11. PubMed ID: 8756388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ewing's sarcoma: evaluation of chemotherapy in 17 cases.
    Ozaki T; Inoue H; Sugihara S; Hamada M; Nakagawa Y; Taguchi K
    Hiroshima J Med Sci; 1993 Jun; 42(2):89-96. PubMed ID: 8253602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli.
    Bacci G; Ferrari S; Bertoni F; Rimondini S; Longhi A; Bacchini P; Forni C; Manfrini M; Donati D; Picci P
    J Clin Oncol; 2000 Jan; 18(1):4-11. PubMed ID: 10623687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study.
    Craft A; Cotterill S; Malcolm A; Spooner D; Grimer R; Souhami R; Imeson J; Lewis I
    J Clin Oncol; 1998 Nov; 16(11):3628-33. PubMed ID: 9817284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone.
    Meyer WH; Kun L; Marina N; Roberson P; Parham D; Rao B; Fletcher B; Pratt CB
    J Clin Oncol; 1992 Nov; 10(11):1737-42. PubMed ID: 1403056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma.
    Jürgens H; Exner U; Kühl J; Ritter J; Treuner J; Weinel P; Winkler K; Göbel U
    Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S40-4. PubMed ID: 2503258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies.
    Dunst J; Ahrens S; Paulussen M; Rübe C; Winkelmann W; Zoubek A; Harms D; Jürgens H
    Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):379-84. PubMed ID: 9788419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.